Windtree to Present at Oppenheimer’s 32nd Annual Healthcare Conference

Rhea-AI Summary

Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that CEO Craig Fraser will present a corporate overview at the Oppenheimer 32nd Annual Healthcare Conference on March 15 at 1:20 p.m. ET. The presentation aims to highlight Windtree's advancements in treatments for acute cardiovascular and pulmonary disorders, primarily focusing on their lead candidate, istaroxime, for acute heart failure. Investors can view the live webcast and subsequent replay on the company's investor page.

WARRINGTON, Pa., March 10, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and be available for 1x1 meetings at the Oppenheimer 32^nd Annual Healthcare Conference on Tuesday, March 15 at 1:20 p.m. Eastern Time.

To view the presentation, click HERE. A live webcast and replay of the presentation will be available on the Investor Page of the company’s website (www.windtreetx.com).

About Windtree Therapeutics
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and acute pulmonary disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for acute heart failure and for early cardiogenic shock. Windtree’s heart failure platform includes follow-on oral pre-clinical SERCA2a activator assets as well. In pulmonary care, Windtree has focused on facilitating the transfer of the clinical development of AEROSURF®, to its licensee in Asia, Lee's HK. Windtree is also evaluating KL4 surfactant for the treatment of acute respiratory distress syndrome in COVID-19 patients. Included in Windtree’s portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

Contact Information:
Monique Kosse
LifeSci Advisors
212.915.3820 or monique@lifesciadvisors.com

Media contact:
Andrew Mielach
LifeSci Communications
646.876.5868 or amielach@lifescicomms.com

 

FAQ

When is the Oppenheimer 32nd Annual Healthcare Conference presentation by Windtree Therapeutics?

Craig Fraser, CEO of Windtree Therapeutics, will present on March 15 at 1:20 p.m. ET.

What is the focus of Windtree Therapeutics' presentation at the Oppenheimer Conference?

The presentation will cover advancements in treatments for acute cardiovascular and pulmonary disorders.

What is istaroxime and its significance for Windtree Therapeutics?

Istaroxime is Windtree's lead candidate for treating acute heart failure and is a first-in-class treatment.

How can investors access the presentation from Windtree Therapeutics?

Investors can view the live webcast and replay on Windtree's investor page after the presentation.

What innovations is Windtree Therapeutics pursuing in pulmonary care?

Windtree is developing AEROSURF® and evaluating KL4 surfactant for treating acute respiratory distress syndrome in COVID-19 patients.